- Research article
- Open Access
- Open Peer Review

# Inference of synergy/antagonism between anticancer drugs from the pooled analysis of clinical trials

- Wenfeng Kang
^{1, 2}, - Robert S DiPaola
^{2}and - Alexei Vazquez
^{1}Email author

**13**:77

https://doi.org/10.1186/1471-2288-13-77

© Kang et al.; licensee BioMed Central Ltd. 2013

**Received:**12 July 2012**Accepted:**7 June 2013**Published:**12 June 2013

## Abstract

### Background

Drug interactions can have a significant impact on the response to combinatorial therapy for anticancer treatment. In some instances these interactions can be anticipated based on pre-clinical models. However, the anticipation of drug interactions in the clinical context is in general a challenging task.

### Methods

Here we propose the pooled analysis of clinical trials as a mean to investigate drug interactions in anticancer therapy. To this end we collected 1,163 Phase II clinical trials with response data on over 53,745 subjects.

### Results

We provide statistical definitions of drugs resulting in clinical synergy and antagonism and identify drug combinations in each group. We also quantify the possibility of inferring interactions between three or more drugs from parameters characterizing the action of single and two-drugs combinations.

### Conclusions

Our analysis provides a statistical methodology to track the performance of drug combinations in anticancer therapy and to quantify drug interactions in the clinical context.

## Keywords

- Cancer therapy
- Clinical trial
- Overall response rate
- Combinatorial therapies
- Clinical synergy
- Systems biology

## Background

Given the low rate of phase III trials success, complimentary options to optimize earlier trial development, especially with combination therapy, would be critically important [1]. The identification of effective drug combinations is, however, a challenging task [2], given the large number of potential targets and agents available or under investigation. For example, 100 FDA approved drugs would result in about 5,000 two-drug combinations, and the number increases exponentially if we consider combinations of multiple agents. Additionally, preclinical drug combination screens explore various concentration ranges for each drug in a combination, making the exhaustive screen of all possible drug combinations difficult. Although preclinical studies historically have helped inform early trial development of combination therapies, the contributory value of phase II trials and ultimate success in identifying agents with a survival impact in phase III trials has been reported to be low, warranting new methodologies [3].

Meta-analyses pooling together many clinical trials have been used to better quantify the performance of a new anticancer treatment (single agents or combinations) relative to a standard treatment [4–7]. We hypothesized that data analyzed across large numbers of clinical trials could also be utilized to obtain an estimate of the interaction between anticancer drugs. Several drug combinations have been tested in clinical trials in the past years, providing a unique resource to understand the response patterns of drug combinations. A typical measure for treatment success is the clinical overall response rate (ORR), defined as the percentage of patients whose cancer shrinks (partial response) or disappears (complete response) after treatment. By observing successful, and unsuccessful, combinations defined by ORR in multiple cancer types we hypothesized that we could identify synergistic drug combinations with a response rate higher than what is expected. In addition to increased response rate, we hypothesized that we could identify drug interactions with antagonistic effects. About 20-30% of all adverse reactions to drugs are caused by interactions between drugs [8], underscoring the need to identify antagonistic drug interactions as well.

Although theoretical foundations for the experimental design to *in vitro* study drug combinations are well established [9], methodologies to assess large and varied clinical datasets are limited. In this work, we develop statistical methodologies to characterize drug interactions directly from clinical data. Specifically, we study the response rates of single drug and drug combinations tested in Phase II clinical trials for their anticancer activity. Our main goal is to uncover general patterns that could inform future approaches aiming to identify effective drug combinations for anticancer treatment.

## Methods

### Study design

To test our statistical methodology, on May 7, 2010, we searched PubMed with the following search key: cancer phase II clinical trial overall response rate. From the list of returned abstracts we selected in order of appearance the first 1,000 clinical trials. This number was chosen to balance the effort of manually extracting the required data from the PubMed abstracts and the desire to include as many trials as possible. Following an initial assessment of our methodology with that subset of clinical trials, on August 9, 2011, we searched PubMed again to extract new reports between this date and the previous search. This resulted 163 additional trials adding to a total of 1,163 trials. The reason for the latter search was to allow us to investigate more recent trends. We did not found any significant differences from the analysis of the initial set of 1,000 trials and the final set of 1,163 trials. The complete list of trials is reported in the Additional file 1. Our primary measure for treatment success was the clinical overall response rate (ORR), defined as the percentage of patients whose cancer shrinks (partial response) or disappears (complete response) after treatment. Recognizing the limitations of comparing response rates for each cancer type across separate trials, we chose the overall response rate as the main outcome measure. This choice was based on the assumption that most phase II trials used standard RECIST response criteria, and were powered for a clinically relevant response rate that could lead to a “go no-go” decision for a phase III study. Overall, 184 agents were tested as single agents or in combination in the collected trials.

### Observed ORR

Each clinical trial reports the number of patients with an overall response (*n*) and the trial sample size (*N*). For a given combination tested in a given trial, *n* is modeled as a random variable following the binomial distribution $P\left(n|N,p\right)=\left(\begin{array}{l}N\\ n\end{array}\right){p}^{n}{\left(1-p\right)}^{N-n}$, where *p* is an unknown parameter representing the probability that a patient manifest a partial or complete response to the treatment. The Bayesian posterior distribution of *p* is given by a beta distribution $P\left(p|n,N\right)=\frac{1}{B\left(\alpha ,\beta \right)}{p}^{\alpha -1}{\left(1-p\right)}^{\beta -1}$, where *α*=*n* and *β*=*N*-*n* and *B*(*α*,*β*) is the beta function (Additional file 2). For a given combination tested in multiple trials, we take into account that *p* may be different due to the use of different dose, schedule or cancer subtype on each trial. To account for these differences, we constructed a statistical methodology that models the existence of multiple classes of trials (among those testing the same combination) with different values of *p* (Additional file 2). In our dataset, there were 166 combinations tested in two or more trials. When pooling the clinical trials by the combination tested, in 142 of these combinations the data indicates that all trials are statistically equivalent as determined by the Bayesian method. In these cases we pooled together the data from clinical trials testing the same combination even though some were conducted in different cancer subtypes. For the remaining 24 combinations, there are significantly different response rates depending on the cancer type. In this latter case the Bayesian method returns two or more groups, each containing one or more cancer types. When each group was represented by only one trial we removed those trials from our search of synergistic/antagonistic combinations. Otherwise we removed the trials in the group with lowest number of trials. The excluded trials are indicated in the Additional file 3. These trials were removed because the reported ORR was inconsistent with the report by trials testing the same combination in the same cancer type. When all trials are statistically equivalent, *p* follows a beta distribution with *α* = ∑_{
i
}
*n*
_{
i
} and *β* = ∑_{
i
}(*N*
_{
i
} − *n*
_{
i
}), where the index *i* runs over all trials testing the combination. The expected probability of response rates is computed from the mean of the beta distribution mean(*p*) = *α*/(*α* + *β*) = ∑_{
i
}
*n*
_{
i
}/∑_{
i
}
*N*
_{
i
}, and the associated ORR is computed as ORR_{0} = 100%×mean(*p*).

### Null model for combinations of two non-interacting agents

In the absence of agent interactions, the probability that a patient responds to a treatment based on two agents equals one minus the probability that he/she does not respond to either treatment: *q*
_{
ij
} = 1 − (1 − *p*
_{
i
})(1 − *p*
_{
j
}), where *p*
_{
i
} and *p*
_{
j
} are the response probabilities for each agent when used as a single agent. The probabilities *p*
_{
i
} were estimated using trials where the agents were tested as single agents. In a trial where *N* patients were treated with the two agents *i* and *j*, we expected *n* responses with a binomial probability distribution $P\left(n|N,{q}_{\mathit{ij}}\right)=\left(\begin{array}{c}\hfill N\hfill \\ \hfill n\hfill \end{array}\right){q}_{\mathit{ij}}^{n}{\left(1-{q}_{\mathit{ij}}\right)}^{N-n}$. We estimated the probability that there was synergy as the probability to obtain as many or more responses given a non-interacting agents hypothesis: ${p}_{\mathit{synergy},\mathit{ij}}={\displaystyle {\sum}_{m=n}^{N}P\left(m|{q}_{\mathit{ij}},N\right)}$. Similarly, we estimated the probability that there was antagonism as the probability to obtain as many or less responses, given a non-interacting hypothesis: ${p}_{\mathit{antagonism},\mathit{ij}}={\displaystyle {\sum}_{m=0}^{n}P\left(m|{q}_{\mathit{ij}},N\right)}$. Finally, the expected ORR under the assumption of non-interacting agents was defined as ORR_{1,ij
} = 100*%*mean(*q*
_{
ij
}) = 100*%*[1 − (1 − mean(*p*
_{
i
}))(1 − mean(*p*
_{
j
}))]. The simulations to test the null (non-interacting) model approach were performed as follows. Given a sample size *N*, uniformingly sampled values between 0 and 1 were generated for the probability of response to drug 1, *p*
_{1}, the probability of response to drug 2, *p*
_{2}, and the probability to respond to the combination of drug 1 and 2, *p*
_{12}. Using the probabilities *p*
_{1} and *p*
_{2}, the probability of response to the combination of drug 1 and 2 in the absence of drug interactions, *q*
_{12} = 1 − (1 − *p*
_{1})(1 − *p*
_{2}), was computed. Then, *n*
_{1}, *n*
_{2} and *n*
_{12} responses out of *N* attempts were generated using a binomial model with probability of success *p*
_{1}, *p*
_{2} and *p*
_{12}, respectively. Using the generated number of responses, the posterior means *p*
_{0,1} = *n*
_{1}/*N*, *p*
_{0,2} = *n*
_{2}/*N* and *p*
_{0,12} = *n*
_{12}/*N* were computed. Finally, using *q*
_{0,12} = 1 − (1 − *p*
_{0,1})(1 − *p*
_{0,2}) and *n*
_{12} as input, *p*
_{
synergy,12} and *p*
_{
antagonism,12} were computed. This procedure was repeated 10,000,000 times. The manifestation of synergy/antagonism was determined by comparing the expected ORR as obtained from the null model ORR_{1} = 100%*q*
_{12} with the ORR as observed ORR_{0} = 100%*p*
_{12}. Specifically, the probability for synergy *p*
_{
synergy,12} was calculated as the fraction of times that ORR_{0}>ORR_{1} and *p*
_{
synergy,12}≥0.05. Similarly, the probability for antagonism *p*
_{
synergy,12} was calculated as the fraction of times that ORR_{0}<ORR_{1} and *p*
_{
antagonism,12}≥0.05. To compute these fractions we divided the [0–1] interval in bins of size 0.01.

### Two-agents approximation to the ORR

In the 2-agent approximation model the ORR for each agent combination *c* is derived from parameters quantifying the response to a single agent and the interaction between two agents. These combinations are constructed out of *N*
_{
a
} agents. The combinations are specified using the agent to combination matrix_{
.
}
*s*
_{
ci
}, where *s*
_{
ci
} = 1 if agent *i* is part of the combination *c* and *s*
_{
ci
} = 0 otherwise. The parameter *h*
_{
i
} denotes the response rate to agent *i* when tested as a single agent. The parameters *J*
_{
ij
} are introduced to quantify corrections due to agent interactions. The probability *p*
_{
c
} to respond to a combination *c* is written as ${p}_{c}={\displaystyle {\sum}_{i=1}^{{N}_{a}}{s}_{\mathit{ci}}{h}_{i}}+{\displaystyle {\sum}_{i=1}^{{N}_{a}-1}{\displaystyle {\sum}_{j=i+1}^{{N}_{a}}{s}_{\mathit{ci}}{s}_{\mathit{cj}}{J}_{\mathit{ij}}}}$ and the associated overall response rate is ORR_{
c
} = 100%×*p*
_{
c
}. To understand the equation for *p*
_{
c
}, it is better to focus on the case when the drugs do not interact. In this case ${p}_{c}=1-{\displaystyle {\prod}_{i=1}^{{N}_{a}}{\left(1-{h}_{i}\right)}^{{s}_{\mathit{ci}}}}={\displaystyle {\sum}_{i=1}^{{N}_{a}}{s}_{\mathit{ci}}{h}_{i}}-{\displaystyle {\sum}_{i=1}^{{N}_{a}-1}{\displaystyle {\sum}_{j=i+1}^{{N}_{a}}{s}_{\mathit{ci}}{s}_{\mathit{cj}}{h}_{i}{h}_{j}}}$. Therefore, in the absence of interactions the equation of *p*
_{
c
} can be written as we postulated above with ${J}_{\mathit{ij}}^{0}=-{h}_{i}{h}_{j}$. The difference between an observed *J*
_{
ij
} and the non-interacting value $\Delta {J}_{\mathit{ij}}={J}_{\mathit{ij}}-{J}_{\mathit{ij}}^{0}$ is used to quantify synergy (when positive) and antagonism (when negative). The 2-agent model can be rewritten as ${p}_{c}={\displaystyle {\sum}_{m=1}^{{N}_{v}}{A}_{\mathit{cm}}{x}_{m}}$, where *N*
_{
v
} is the number of variables (unknown *hs* and *Js*), the *x*
_{
m
} are variables representing the *hs* and *Js* parameters, and *A*
_{
cm
} is the variable to a combination matrix (*A*
_{
cm
} = 1 if variable *m* appears in the equation for combination *c* and *A*
_{
cm
} = 0 otherwise). The variables *x*
_{
m
} were estimated by solving the corresponding least-squares problem, with some additional considerations to account for the variability in the empirical estimates of *p*
_{
c
} (Additional file 2). The 2-agent approximation to the ORR was given by ORR_{2,ij
} = 100*%*[∑_{
i
}
*s*
_{
ci
}mean(*h*
_{
i
}) + ∑ _{
i <j
}
*s*
_{
ci
}
*s*
_{
cj
}
*mean*(*J*
_{
ij
})].

### Kolmogorov-smirnov test

The kolmogorov-smirnov test [10] was used to determine the probability that two lists of ORRs were generated from the same distribution.

## Results and discussion

### Statistical equivalence of trials testing the same combination

The response rate to a combination of agents may depend on the dose of each agent, the treatment schedule, and the cancer subtype. We developed a statistical methodology that determines if a set of trials testing the same combination is statistically equivalent, or if there are trials with statistically different response rates. To this end, we developed a Bayesian method that takes into account the variations in the estimated response rates due to finite sample sizes. This Bayesian method determines whether the number of responses reported in a set of clinical trials are consistent with a unique response rate, up to variations determined by the finite sample sizes, or whether the trials cluster in two or more groups with statistically significant response rates. In our dataset, there were 166 agent combinations that were tested by two or more clinical trials. In 142 combinations the observed response rates were statistically equivalent. Only in 24 combinations there is evidence of trials with statistically different response rates (Additional file 3).

We note that the observation of statistical equivalence does not imply that the response rates do not depend on dose or cancer type. By necessity, we made the assumption that in most trials within the dataset studied, the agent doses are standard based on standard maximal tolerated doses defined by prior phase I trials. Response rates were also comparable because similar agent combinations or combinations of similar drug class were usually tested in the same cancer subtype. We recognized that targeted therapies were often used to treat patients selected on the basis of a companion biomarker. For example, within the studied dataset, there were 32 trials testing trastuzumab as a single agent or in combination. In all cases the patients enrolled were Her2/neu+, the target of trastuzumab. Although we assumed that within the studied dataset the trials associated with the same agent combination are statistically equivalent, we acknowledged that in some instances the results that follow are biased towards specific cancer subtypes. For example, all the interactions with trastuzumab are relevant in the context of Her2/neu+patients and interactions with radiation are relevant in the context of localized disease. These biases will be reported when necessary.

### Trends as a function of the number of agents combined

### Targeted vs non-targeted therapies

Among the 514 combinations tested, 85 included novel monoclonal antibodies, allowing us to test whether targeted therapies are improving response rates. As expected, based on prior randomized trials, the distribution of posterior mean ORRs for trials testing monoclonal antibodies was shifted toward higher ORRs relative to the distribution for trials not including monoclonal antibodies (54% vs 46%, p-value of 0.0042 based on a Kolmogorov-Smirnov test). Furthermore, the median over posterior ORRs was higher for combinations including monoclonal antibodies independently of the number of agents in the combination (Figure 1), with the exception of combinations with four agents.

### Clinical synergy

We then focused on agent combinations resulting in trials with ORRs that were significantly different than what expected from a null model with no interactions between the agents tested. From the clinical point of view, a combination was deemed *synergistic* when its ORR was significantly higher than what was expected from the null model of non-interacting agents, and *antagonistic* when significantly lower. The null model for non-interacting drug combinations is mathematically described in the methods section. In simple words, in the absence of drug interactions the probability that a patient responds to a two-drug combination is equal to the probability that he/she responds to at least one drug in the combination. The probability that a patient responds to at least one drug in the combination can be estimated using as input the trials testing the drugs as single agents. Once we have an estimate of the probability that a patient responds to the two-drug combination in the absence of interactions, we can determine the probability to observe as many or more responses in a trial with a given sample size (*p*
_{
synergy
}), the probability to observe as many or less responses (*p*
_{
antagonism
}) and the expected response rate in the absence of drug interactions ORR_{1}.

_{0}) deviates from what expected from the null model for non-interacting drugs (ORR

_{1}).

*p*

_{ synergy }< 0.05), antagonistic (

*p*

_{ antagonism }< 0.05) or non-interacting (

*p*

_{ synergy }≥0.05 and

*p*

_{ antagonism }≥0.05). Table 1 and 2 report the two-agent combinations with evidence for synergy and antagonism, respectively. About half of the predicted synergistic combinations are the standard of care in specific cancer types (e.g., docetaxel+doxorubicin in breast cancer), indicating that our analysis captures the current trends in cancer treatment (Table 1). The remaining synergistic combinations should be further studied to evaluate their potential to improve cancer treatment. In contrast, only one antagonistic drug combinations is currently used as standard of care for the corresponding cancer subtypes (Table 2).

**Synergistic 2**-**agent combinations**

Agent 1 | Agent 2 | Standard of care* | Expected | Observed |
| Cancer subtype |
---|---|---|---|---|---|---|

Docetaxel | Doxorubicin | Yes | 40 | 65 | 7.70E-43 | Breast cancer |

Oxaliplatin | 5-fluorouracil | Yes | 25 | 52 | 1.82E-17 | Colorectal, gastric cancer |

Irinotecan | Etoposide | No | 19 | 66 | 4.98E-13 | Lung cancer |

Doxorubicin | Ifosfamide | Yes | 19 | 48 | 1.20E-09 | Gynecologic, soft tissue sarcoma |

Bortezomib | Thalidomide | Yes | 56 | 100 | 2.13E-09 | Myeloma |

Capecitabine | Irinotecan | No | 35 | 48 | 9.53E-09 | Colorectal, gastric, lung cancer |

S-1 | Irinotecan | No | 33 | 47 | 1.20E-07 | Colorectal, gastric, lung cancer |

Oxaliplatin | Doxorubicin | No | 27 | 68 | 1.30E-07 | Ovarian cancer |

Oxaliplatin | Irinotecan | Yes | 24 | 52 | 4.30E-06 | Colorectal, lung cancer |

Capecitabine | Radiation | No | 65 | 88 | 3.11E-05 | Cervical cancer |

Rituximab | Alpha-interferon | No | 67 | 94 | 2.48E-04 | Lymphoma |

Oxaliplatin | Capecitabine | Yes | 38 | 44 | 3.41E-03 | Colorectal, gastric cancer |

5-fluorouracil | Irinotecan | Yes | 22 | 38 | 5.87E-03 | Colorectal cancer |

Capecitabine | Alpha-interferon | No | 38 | 54 | 3.34E-02 | Renal cancer |

Fludarabine | Thalidomide | No | 78 | 100 | 4.05E-02 | Leukemia |

**Antagonistic 2**-**agents combinations**

Agent 1 | Agent 2 | Standard of care* | Expected | Observed |
| Cancer subtype |
---|---|---|---|---|---|---|

Docetaxel | Topotecan | No | 42 | 12 | 2.94E-11 | Lung, ovarian cancer |

Bortezomib | Rituximab | No | 78 | 53 | 1.20E-09 | Lymphoma |

Temozolomide | Alpha-interferon | No | 38 | 18 | 5.87E-08 | Melanoma |

Capecitabine | Bortezomib | No | 58 | 14 | 9.02E-08 | Breast cancer |

Fludarabine | Alemtuzumab | No | 83 | 64 | 1.27E-07 | CLL, leukemia |

Bevacizumab | Temozolomide | No | 48 | 16 | 1.41E-07 | Melanoma |

Capecitabine | Trimetrexate | No | 45 | 6 | 2.15E-06 | Colorectal cancer |

Docetaxel | Irinotecan | No | 37 | 18 | 1.15E-05 | Gastric, lung, ovarian cancer |

Bortezomib | Temsirolimus | No | 64 | 30 | 1.25E-05 | Myeloma |

Temozolomide | Interleukin-2 | No | 49 | 16 | 1.97E-05 | Melanoma |

Docetaxel | Gefitinib | No | 71 | 31 | 2.29E-05 | Lung cancer |

Docetaxel | 5-fluorouracil | No | 38 | 25 | 1.71E-04 | Gastric, head and neck cancer |

Rituximab | Temsirolimus | No | 75 | 59 | 2.44E-03 | Lymphoma |

Temozolomide | Radiation | No | 64 | 46 | 2.51E-03 | Breast cancer |

Fludarabine | Alpha-interferon | No | 76 | 52 | 2.55E-03 | Lymphoma |

G-CSF | Rituximab | No | 71 | 61 | 4.69E-03 | CLL, lymphoma |

Doxorubicin | Bevacizumab | No | 40 | 21 | 9.11E-03 | Breast cancer |

Docetaxel | Imatinib | No | 46 | 28 | 2.09E-02 | Breast cancer |

Docetaxel | Capecitabine | Yes | 49 | 43 | 4.48E-02 | Breast, gastric cancer |

Vinorelbine | Mitoxantrone | No | 42 | 29 | 4.62E-02 | Breast cancer |

We tested the hypothesis that synergy was more common in combinations using monoclonal antibodies, a class of targeted therapies. However, only 1 out 15 combinations in the list of synergistic 2-agent combinations included at least one monoclonal antibody (Table 1, rituximab+alpha-interferon). Although a small sample size, requiring future validation, these data support a lack of significant enrichment of synergy by the addition of a monoclonal antibody relative to other agent combinations (*p*-value = 0.99, Fischer’s exact test). This observation may also indicate that synergy is as common between chemotherapeutic agents as between a chemotherapeutic agent and a monoclonal antibody.

### Quantifying agent interactions using a 2-agent approximation

_{2}) as a function of the mean ORR empirical estimates (ORR

_{0}). We noticed that in most cases the predicted ORRs were lower than the empirical estimates, as can be deduced from the higher density of points in the lower-right triangle in Figure 3. Indeed, in 77, 76 and 69% of the combinations with 1, 2 and 3 or more agents, respectively, the predicted ORR was lower than the empirical estimate (ORR

_{2}<ORR

_{0}). Therefore, the 2-agent approximation can be used to estimate a lower bound to the ORR. More precisely, with about 75% confidence, the actual ORR is higher than what predicted by the 2-agent approximation. In practical terms this means that when the 2-agent approximation predicts a high ORR, with about 75% confidence we should expect as high or higher responses rates. On the other hand, if the 2-agent approximation predicts a low ORR, the prediction become less informative, since likely the ORR will actually be higher. Using the 2-agent approximation we estimated the ORR of all 2-agent combinations, provided that the two agents appeared together in at least one trial within our dataset (Additional file 4). We noted again that these predictions were likely underestimating the actual ORR. We also noted that these predictions were subject to the same biases discussed above. If an agent has been tested in a specific cancer subtype, then the predicted ORRs for combinations using that agent are expected to be valid within that subtype.

## Conclusions

Statistical and systems biology methodologies have been proposed for the rational discovery of combinatorial therapies [2]. Our ability to test the performance of these methodologies is limited, however, by the availability of a catalog of synergistic drug combinations. Similarly, a catalog of drugs with antagonistic interactions could help to design statistical and systems biology methodologies to anticipate adverse drug interactions [8]. We propose the pooled analysis of Phase II clinical trials as a methodology to develop a catalog of synergistic and antagonistic drug combinations. This catalog can be used as a gold standard for testing methodologies attempting to infer the interactions between drugs in the treatment of cancer. Here we provide a preliminary version of this catalog, derived from the analysis of 1,163 clinical trials and 53,745 subjects. The synergistic 2-agent combinations are reported in Table 1 and the antagonistic two-agent combinations in Table 2.

The pooled analysis of this data supports the hypothesis that the ORR increases with increasing the number of drugs used in combination, from 25% for single agents to about 85% for five drugs combinations. In most cases, this increase is explained by the additive effect of the drugs in the combination. However, for certain combinations, the ORRs are significantly greater than what would be expected from the additive effects of the two drugs, which represent our predicted synergistic drug combinations. On the other hand, there were also drug combinations with ORRs significantly below what is expected from their additive effects, which represent antagonistic drug combinations.

To evaluate the impact of targeted therapies, we focused on monoclonal antibodies. We recognize that there are many different and emerging targeted therapies such as kinase inhibitors. However, monoclonal antibodies were the only class present in a sufficient number to conduct the analysis. We observe a significant 8% increase in the average ORR of trials using monoclonal antibodies, indicating that these targeted therapies are indeed improving the response rates. However, among the reported synergistic combinations, there was not a significant enrichment of combinations using monoclonal antibodies. Based on this evidence, we conclude that synergy is as common between chemotherapeutic agents as between a chemotherapeutic agent and a monoclonal antibody. These methodologies will be more important as ongoing studies are now assessing more combinations of targeted agents with standard chemotherapy as well as combinations of targeted agents.

Using a 2-agent approximation we estimated the ORR of all combinations of two agents, provided the two agents were tested together, alone or in combination with other agents, in at least one clinical trial. A cross-validation analysis revealed that this 2-agent approximation provides a good lower bound estimate of the ORR. In practical terms, this means that the combinations with predicted high ORRs are quite likely to manifest high ORRs, but if the ORR is predicted to be low, then the prediction is not informative. The 2-agent approximation predictions, reported in the Additional file 4, can be used as a reference to prioritize further testing of combination therapy for cancer treatment.

The *in vitro* definition of synergy based on growth inhibition assays [9] does not necessarily predicts clinical synergy, because of drug metabolism or other factors. For example, an *in vitro* study using breast cancer cell lines, it was reported that the combination docetaxel+doxorubicin was antagonistic, while the combination docetaxel+epirubicin was synergistic [11]. In contrast, we found that the combination docetaxel+doxurubicin was synergistic based on the Phase II trials clinical data of breast cancer, while the combination of docetaxel+epirubicin was antagonistic, albeit in lung cancer. This example emphasizes that *in vitro* evidence for synergy, while potentially informative, should not be the gold standard, underscoring the need for gold standards of synergy in the clinical context.

In a more general perspective, this analysis opens the question of whether we should test both new treatments and the standard of care on each trial, or whether we should test only the new treatments in new trials and compare the results against the gold standard library. This may be particularly relevant to efforts to improve trial efficiency in order to test multiple targeted new agents in combination. Clearly, given the ORR of a new treatment, we can provide estimates of clinical benefit and synergy using our methodology. Looking ahead, the statistical methodology developed in this work can be further tested and validated with expanded phase II clinical trial data sets, more specific data sets, and in prospective predictions of new combinations moving into phase II studies.

## Declarations

### Financial support

WK and AV were sponsored by the RWJ Foundation. WK, RSD and AV were supported by NCI P30 CA072720.

## Authors’ Affiliations

## References

- Kummar S, Chen HX, Wright J, Holbeck S, Millin MD, Tomaszewski J, Zweibel J, Collins J, Doroshow JH: Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. Nat Rev Drug Discov. 2010, 9 (11): 843-856. 10.1038/nrd3216.View ArticlePubMedGoogle Scholar
- Feala JD, Cortes J, Duxbury PM, Piermarocchi C, McCulloch AD, Paternostro G: Systems approaches and algorithms for discovery of combinatorial therapies. Wiley Interdiscip Rev Syst Biol Med. 2010, 2 (2): 181-193. 10.1002/wsbm.51.View ArticlePubMedGoogle Scholar
- Maitland ML, Hudoba C, Snider KL, Ratain MJ: Analysis of the yield of phase II combination therapy trials in medical oncology. Clin Cancer Res. 2010, 16 (21): 5296-5302. 10.1158/1078-0432.CCR-10-0669.View ArticlePubMedPubMed CentralGoogle Scholar
- Belfiglio M, Fanizza C, Tinari N, Ficorella C, Iacobelli S, Natoli C: Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer. J Cancer Res Clin Oncol. 2012, 138 (2): 221-229. 10.1007/s00432-011-1091-0.View ArticlePubMedGoogle Scholar
- Rossari JR, Metzger-Filho O, Paesmans M, Saini KS, Gennari A, De Azambuja E, Piccart-Gebhart M: Bevacizumab and breast cancer: a meta-analysis of first-line phase III studies and a critical reappraisal of available evidence. J Oncol. 2012, 2012: 417673-View ArticlePubMedPubMed CentralGoogle Scholar
- Wu X, Jin Y, Cui IH, Xu Z, Zhang Y, Zhang X, Tang C, Gong Y, Chen J: Addition of vandetanib to chemotherapy in advanced solid cancers: a meta-analysis. Anticancer Drugs. 2012, 23 (7): 731-738. 10.1097/CAD.0b013e32835514f4.View ArticlePubMedGoogle Scholar
- Gao G, Chu H, Zhao L, Gui T, Xu Q, Shi J: A meta-analysis of paclitaxel-based chemotherapies administered once every week compared with once every 3 weeks first-line treatment of advanced non-small-cell lung cancer. Lung Cancer. 2012, 76 (3): 380-386. 10.1016/j.lungcan.2011.12.001.View ArticlePubMedGoogle Scholar
- Scripture CD, Figg WD: Drug interactions in cancer therapy. Nat Rev Cancer. 2006, 6 (7): 546-558. 10.1038/nrc1887.View ArticlePubMedGoogle Scholar
- Chou TC: Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006, 58 (3): 621-681. 10.1124/pr.58.3.10.View ArticlePubMedGoogle Scholar
- Wilcox RR: Introduction to robust estimation and hypothesis testing. 2005, Amsterdam, Boston: Elsevier/Academic Press, 2Google Scholar
- Budman DR, Calabro A: In vitro search for synergy and antagonism: evaluation of docetaxel combinations in breast cancer cell lines. Breast Cancer Res Treat. 2002, 74 (1): 41-46. 10.1023/A:1016070230538.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2288/13/77/prepub

### Pre-publication history

## Copyright

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.